Selective Inhibitors of Nuclear Exports—A Novel Anti-Cancer Drug Class: The Review Study

Authors

  • Maria Ayub Jinnah University for women
  • Soofia Islam
  • Qurat -ul- Ainriaz
  • Amna Islam

DOI:

https://doi.org/10.37591/rrjodfdp.v5i1.123

Keywords:

Nuclear export, SINEs, kpt-330, selinexor, various malignancies

Abstract

For the maintenance of cell homeostasis nucleus-cytoplasmic transport is of great concern. The transport is basically depending on a size of molecule. In different hematological and solid malignancies, the CRM1 is overexpressed so the agents are requiring that particularly inhibit the exportins of nuclear export. This concept favors the SINEs development. The objective of this review study is to understand all about the novel anticancer drugs and their uses in various hematological and solid tumors. The data is carefully extracted from literature review studies of PubMed specifically. On the basic consideration of the studies, it was concluded that SINEs have a very progressive antitumor activities and it shows less interaction with drugs. However, it has synergism edicts along with other anticancer agents, so that they treat disease easily and on early basis as well e.g. combination of BRAF inhibitors/MEK inhibitors/SINEs for treating the breast cancer. The first drug that represents a novel anticancer class was Selinaxor (KPT-330).

 

Keywords: Nuclear export, SINEs, KPT-330, Selinaxor, various malignancies

 

Cite this Article

Maria Ayub, Soofia Islam, Qurat-ul-Ainriaz et al. Selective Inhibitors of Nuclear Exports—A Novel Anti-Cancer Drug Class: The Review Study. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2018; 5(1): 29–36p.

Downloads

Published

2018-07-16

Issue

Vol. 5 No. 1 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.